Treatment with anti-ErbB2 antibodies

• US 20030086924A1
• Filed: 10/10/2002
• Published: 05/08/2003
• Est. Priority Date: 06/25/1999
• Status: Abandoned Application

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Sliwkowski, Mark X.
• Application Number:
  US10/268,501
• Publication Number:
  US 20030086924A1
• Time in Patent Office: Days
• US Class Current: 424/143.1
• CPC Class Codes: A61K 47/6809 Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
• CPC Class Codes: C07K 16/32 against translation products of oncogenes

Abstract

The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.

Claims

1. A method of treating cancer that expresses ErbB2 selected from the group consisting of carcinoma, lymphoma, blastoma, sarcoma, liposarcoma, neuroendocrine tumor, mesothelioma, schwanoma, meningioma, adenocarcinoma, melanoma, leukemia, lymphoid malignancy, squamous cell cancer, epithelial squamous cell cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophagael cancer, a tumor of the biliary tract, and head and neck cancer, comprising administering a therapeutically effective amount of an antibody which binds ErbB2 to a patient.

2. The method of claim 1 wherein the antibody blocks ligand activation of an ErbB receptor.

3. The method of claim 1 wherein the antibody blocks binding of monoclonal antibody 2C4 to ErbB2.

4. The method of claim 1 wherein the antibody is monoclonal antibody 2C4 or humanized 2C4.

5. The method of claim 1 wherein the antibody is monoclonal antibody 4D5 or humanized 4D5.

6. A method of treating cancer that expresses ErbB2 comprising administering to a human a therapeutically effective amount of an antibody which binds ErbB2 and a therapeutically effective amount of a second drug selected from the group consisting of an EGFR targeted drug and a tyrosine kinase inhibitor, wherein the antibody and the second drug are administered separately or in combination, and in either order.

7. The method of claim 6 wherein the second drug is an EGFR targeted drug.

8. The method of claim 7 wherein the EGFR targeted drug is selected from the group consisting of MAb 579;

MAb 455;

MAb 225;

MAb 528;

chimerized 225 (C225);

reshaped human 225 (H225);

antibody that binds type II mutant EGFR;

humanized or chimeric antibody that binds EGFR;

human antibody that binds EGFR;

ABX-EGF;

anti-EGFR antibody conjugated with a cytotoxic agent;

ZD1839 (Gefitinib);

CP-358774;

AG1478; and

AG1571.

9. The method of claim 6 wherein the second drug is a tyrosine kinase inhibitor.

10. The method of claim 9 wherein the tyrosine kinase inhibitor is selected from the group consisting of quinazoline;

PD 153035,4-(3-chloroanilino) quinazoline;

pyridopyrimidine;

pyrimidopyrimidine;

pyrrolopyrimidine;

CGP 59326;

CGP 60261;

CGP 62706;

pyrazolopyrimidine, 4-(phenylamino)-7H-pyrrolo[2,3-d] pyrimidine;

curcumin (diferuloyl methane, 4,5-bis (4-fluoroanilino)phthalimide);

tyrphostine containing a nitrothiophene moiety;

PD-0183805;

antisense molecule that binds to ErbB-encoding nucleic acid;

quinoxaline;

tryphostin;

ZD6474;

PTK-787;

pan-ErbB inhibitor;

CI-1033;

Affinitac (ISIS

     3521);

Imatinib mesylate;

PKI 166;

GW2016;

CI-1033;

EKB-569;

Semaxinib;

ZD6474;

PTK-787; and

INC-IC11.

11. The method of claim 6 wherein the antibody blocks ligand activation of an ErbB receptor.

12. The method of claim 6 wherein the antibody blocks binding of monoclonal antibody 2C4 to ErbB2.

13. The method of claim 6 wherein the antibody is monoclonal antibody 2C4 or humanized 2C4.

14. The method of claim 6 wherein the antibody is monoclonal antibody 4D5 or humanized 4D5.